文献速递肝病消化道肿瘤与早癌

酒精性肝硬化肝癌监测的成本效益阈值研究

Optimal Incidence Threshold for Cost-Effective Hepatocellular Carcinoma Surveillance in Alcohol-Associated Cirrhosis.
PubMed 文献 · Clin Gastroenterol Hepatol · 2026-10-15

该研究采用马尔可夫微观模拟模型,评估美国酒精性肝硬化患者每半年一次超声联合甲胎蛋白监测的成本效益。结果显示,当肝癌年发病率超过0.45/100人年时监测即具成本效益,低于传统1/100人年阈值;活动饮酒者与戒酒者的增量成本效益比分别为18,952美元/质量调整生命年和56,000美元/质量调整生命年。

要点

  • 酒精性肝硬化肝癌监测成本效益阈值为年发病率0.45/100人年。
  • 活动饮酒者监测的增量成本效益比为18,952美元/QALY。
  • 戒酒者监测的增量成本效益比为56,000美元/QALY。

核心结论

  • 在美国酒精性肝硬化患者中,当肝癌年发病率超过0.45/100人年时,每半年一次超声联合甲胎蛋白监测具有成本效益。

研究设计与样本

  • 研究采用马尔可夫状态转移微观模拟模型,模拟美国酒精性肝硬化患者的肝癌自然史及治疗路径。
  • 模型分别比较活动饮酒者和持续戒酒者接受每半年一次超声联合甲胎蛋白监测与不监测的成本效益。

主要发现

  • 以每质量调整生命年10万美元支付意愿阈值计算,年发病率约0.45/100人年时监测开始具有成本效益。
  • 活动饮酒者监测的增量成本效益比为18,952美元/QALY,戒酒者为56,000美元/QALY。
  • 每10万患者中,活动饮酒者监测可额外获得2083生命年和992质量调整生命年。
  • 每10万患者中,戒酒者监测可额外获得3357生命年和1700质量调整生命年。

关键数值与推荐

  • 成本效益阈值:年肝癌发病率约0.45/100人年,支付意愿阈值为100,000美元/QALY。
  • 活动饮酒者增量成本效益比:18,952美元/QALY;戒酒者:56,000美元/QALY。

临床怎么用

  • 对于酒精性肝硬化患者,可考虑将肝癌监测的启动阈值下调至年发病率0.45/100人年,而非传统1/100人年。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Current guidelines recommend routine hepatocellular carcinoma (HCC) surveillance in patients with cirrhosis when annual HCC incidence exceeds 1 per 100 person-years, a threshold derived from older studies and not specific to alcohol-associated cirrhosis. However, contemporary data suggest that HCC incidence in this population is often below 1%, leaving the value of routine surveillance uncertain. METHODS: We developed a Markov-based state-transition microsimulation model to simulate the natural history of HCC and subsequent treatment pathways in patients with alcohol-associated cirrhosis in the setting of the United States. The model compared biannual surveillance with ultrasound and alpha fetoprotein vs no surveillance separately for 2 distinct cohorts: patients who continued to actively consume alcohol and patients who had achieved sustained abstinence. Inputs included the natural history of alcohol-associated cirrhosis, HCC incidence, test performance, surveillance adherence, and contemporary treatment. Sensitivity analyses examined the robustness of model assumptions and findings. RESULTS: Biannual surveillance becomes cost-effective when annual HCC incidence reached approximately 0.45 per 100 person-years using a willingness-to-pay threshold of $100,000 per quality-adjusted life year (QALY). Among active drinkers, surveillance yielded an incremental cost-effectiveness ratio of $18,952 per QALY; among abstinent patients, the incremental cost-effectiveness ratio was $56,000 per QALY. Per 100,000 patients, routine surveillance generated an estimated 2083 additional life-years and 992 QALYs in active drinkers and 3357 life-years and 1700 QALYs in abstinent patients. CONCLUSIONS: Routine biannual HCC surveillance with ultrasound and alpha fetoprotein is cost-effective for patients with alcohol-associated cirrhosis in the United States when HCC incidence exceeds 0.45 per 100 person-years, substantially below the historically cited 1 per 100 person-years threshold. Updating clinical guidelines to reflect these contemporary thresholds could improve early HCC detection in this high-risk population.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Hajjar A, Julien J, Nemutlu G, et al. Optimal Incidence Threshold for Cost-Effective Hepatocellular Carcinoma Surveillance in Alcohol-Associated Cirrhosis. Clin Gastroenterol Hepatol. 2026. PMID: 42880653. doi:10.1016/j.cgh.2026.09.035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。